• SELLAS Life Sciences Group reported that its pivotal Phase 3 REGAL trial of galinpepimut-S in second-remission AML has hit the 80th death event, triggering final overall survival analysis, while SLS009 produced encouraging Phase 2 data in difficult relapsed or refractory AML settings.
• The combination of an event-driven Phase 3 readout for GPS and advancing SLS009 into frontline AML trials highlights how SELLAS Life Sciences is concentrating resources on potentially complementary approaches across both maintenance and active disease treatment settings.
• The next area of focus is how SELLAS Life Sciences’ approaching REGAL topline data could reshape the investment narrative around its AML pipeline.

Seize this moment in AML drug…